Compare Stocks

Date Range: 

 Allena PharmaceuticalsBioCardiaaTyr PharmaOrganovoKiromic BioPharma
SymbolNASDAQ:ALNANASDAQ:BCDANASDAQ:LIFENASDAQ:ONVONASDAQ:KRBP
Price Information
Current Price$1.16$3.37$3.85$7.12$6.90
52 Week RangeBuyBuyBuyN/AN/A
MarketRank™
Overall Score1.31.21.50.71.0
Analysis Score3.43.33.50.00.0
Community Score2.61.22.32.55.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.80.80.0
Earnings & Valuation Score0.60.60.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/AN/A
Consensus Price Target$10.40$9.25$16.25N/AN/A
% Upside from Price Target796.55% upside174.48% upside322.08% upsideN/AN/A
Trade Information
Market Cap$66.83 million$56.59 million$61.64 million$52.31 million$50.60 million
Beta2.391.982.170.85N/A
Average Volume1,817,283249,2161,177,499302,57219,142
Sales & Book Value
Annual RevenueN/A$710,000.00$420,000.00$2.20 millionN/A
Price / SalesN/A79.71146.7723.03N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.73 per share$0.35 per share$5.40 per share$4.08 per shareN/A
Price / BookN/A9.630.711.75N/A
Profitability
Net Income$-47,340,000.00$-14,710,000.00$-23,600,000.00$-18,710,000.00N/A
EPS($2.10)($2.61)($7.03)N/AN/A
Trailing P/E RatioN/AN/AN/A0.000.00
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-5,103.95%-202.02%N/AN/A
Return on Equity (ROE)-207.07%-496.87%-52.75%-71.01%N/A
Return on Assets (ROA)-112.21%-178.90%-38.40%-67.22%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.54%0.05%N/AN/AN/A
Current Ratio7.99%1.99%4.76%29.61%N/A
Quick Ratio7.99%1.99%4.76%29.61%N/A
Ownership Information
Institutional Ownership Percentage28.03%9.01%55.82%48.67%N/A
Insider Ownership Percentage22.80%40.90%9.44%5.10%N/A
Miscellaneous
Employees412440719
Shares Outstanding57.61 million16.79 million16.01 million7.12 million7.33 million
Next Earnings Date8/4/2021 (Estimated)5/21/2021 (Estimated)5/13/2021 (Confirmed)N/A6/30/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Kiromic BioPharma, Inc. (NASDAQ:KRBP) Sees Significant Growth in Short InterestKiromic BioPharma, Inc. (NASDAQ:KRBP) Sees Significant Growth in Short Interest
americanbankingnews.com - May 4 at 3:46 AM
Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker EngineKiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker Engine
finance.yahoo.com - May 3 at 1:12 PM
Kiromic Biopharma Inc (KRBP)Kiromic Biopharma Inc (KRBP)
investing.com - April 18 at 10:45 PM
Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate ProgressKiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate Progress
finance.yahoo.com - March 31 at 2:02 PM
Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money ReportKiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
finance.yahoo.com - March 26 at 1:39 PM
Updated fishing forecasts available for Georgia anglersUpdated fishing forecasts available for Georgia anglers
yahoo.com - March 11 at 1:35 PM
This hot mustard sauce passes the zest testThis hot mustard sauce passes the zest test
yahoo.com - March 11 at 1:35 PM
Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid TumorsKiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors
finance.yahoo.com - March 9 at 7:38 PM
Kiromic Announces License Agreement With Longwood University for chPD1Kiromic Announces License Agreement With Longwood University for chPD1
finance.yahoo.com - January 26 at 7:04 PM
Kiromic Announces the Completion of its GMP...Kiromic Announces the Completion of its GMP...
benzinga.com - January 20 at 1:59 AM
Kiromic Announces the Completion of its GMP Manufacturing Facility in Houston, Texas, to Support the Manufacturing of the First In-Human Allogenic CAR-T TrialKiromic Announces the Completion of its GMP Manufacturing Facility in Houston, Texas, to Support the Manufacturing of the First In-Human Allogenic CAR-T Trial
finance.yahoo.com - January 20 at 1:59 AM
Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) TargetKiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target
finance.yahoo.com - January 4 at 11:19 PM
Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDAKiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA
finance.yahoo.com - December 17 at 2:30 PM
Kiromic BioPharma, Inc. Rings the Nasdaq Stock Market Closing Bell in Celebration of its IPOKiromic BioPharma, Inc. Rings the Nasdaq Stock Market Closing Bell in Celebration of its IPO
nasdaq.com - December 4 at 7:38 AM
Kiromic BioPharma, Inc. Rings the Closing Bell in Celebration of its IPOKiromic BioPharma, Inc. Rings the Closing Bell in Celebration of its IPO
nasdaq.com - December 3 at 4:36 PM
DateCompanyBrokerageAction
10/1/2020Allena PharmaceuticalsB. RileyBoost Price Target
9/10/2020Allena PharmaceuticalsWedbushReiterated Rating
9/10/2020Allena PharmaceuticalsHC WainwrightReiterated Rating
7/15/2020Allena PharmaceuticalsRoth CapitalReiterated Rating
7/15/2020Allena PharmaceuticalsLADENBURG THALM/SH SHReiterated Rating
2/17/2020Allena PharmaceuticalsCredit Suisse GroupReiterated Rating
11/14/2019Allena PharmaceuticalsCowenReiterated Rating
4/22/2021BioCardiaDawson JamesReiterated Rating
9/21/2020BioCardiaAlliance Global PartnersInitiated Coverage
8/14/2020BioCardiaMaxim GroupInitiated Coverage
11/26/2019BioCardiaBrookline Capital ManagementReiterated Rating
5/10/2021aTyr PharmaLaidlawInitiated Coverage
3/30/2021aTyr PharmaOppenheimerBoost Price Target
8/30/2019aTyr PharmaCitigroupSet Price Target
3/26/2019aTyr PharmaWilliam BlairReiterated Rating
10/8/2018aTyr PharmaPiper Jaffray CompaniesLower Price Target
8/15/2018aTyr PharmaBMO Capital MarketsLower Price Target
7/27/2018OrganovoJefferies Financial GroupReiterated Rating
(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.